AI & RoboticsNews

Scaling AI: The 4 challenges you’ll face

Organizations of all sizes are embracing AI as a transformative technology to power their digital transformation journeys. Still the challenges around operationalizing AI at scale can still seem insurmountable, with a large number of projects failing. I’ve worked in big data and AI with several organizations and have seen some clear trends on why AI efforts are floundering after an enthusiastic…
Read more
AI & RoboticsNews

AI progress depends on us using less data, not more

In the data science community, we’re witnessing the beginnings of an infodemic — where more data becomes a liability rather than an asset. We’re continuously moving towards ever more data-hungry and more computationally expensive state-of-the-art AI models. And that is…
AI & RoboticsNews

AI Weekly: Techno-utopianism in the workplace and the threat of excessive automation

Every so often, VentureBeat writes a story about something that needs to go away. A few years back, my colleague Blair Hanley Frank argued that AI systems like Einstein, Sensei, and Watson must go because corporations tend to overpromise results for their products and services. I’ve taken runs at charlatan AI and white supremacy. This week, a series of events at the intersection of the…
Read more
AI & RoboticsNews

Bowery CTO Injong Rhee on the grand challenge of AI for indoor farming

In recent years, AI leaders have urged machine learning experts to consider understanding the world’s oceans and tackling climate change grand challenges on par with building autonomous vehicles, beating a computer at a game of chess, or robotic grasping. Combining computer vision, logistics, robotics, and the science of botany, indoor farming has the potential to change human lives. But…
Read more
AI & RoboticsNews

BigHat raises $19 million for an AI-powered antibody design platform

BigHat Biosciences, a protein therapeutics startup and developer of an AI-guided antibody design platform, today announced it has closed a $19 million series A round led by Andreessen Horowitz. A spokesperson told VentureBeat the funding will be used to invest in R&D as BigHat further refines its antibody engineering processes. The use of biologics —  medications made of components like…
Read more